Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial
Open Access
- 5 August 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 107 (13), 1791-1800
- https://doi.org/10.1002/bjs.11760
Abstract
Background Active surveillance has been proposed for patients with oesophageal cancer in whom there is a complete clinical response after neoadjuvant chemoradiotherapy (nCRT). However, endoscopic biopsies have limited negative predictive value in detecting residual disease. This study determined the location of residual tumour following surgery to improve surveillance and endoscopic strategies. Methods The present study was based on patients who participated in the prospective preSANO trial with adenocarcinoma or squamous cell carcinoma of the oesophagus or oesophagogastric junction treated in four Dutch hospitals between 2013 and 2016. Resection specimens and endoscopic biopsies taken during clinical response evaluations after nCRT were reviewed by two expert gastrointestinal pathologists. The exact location of residual disease in the oesophageal wall was determined in resection specimens. Endoscopic biopsies were assessed for the presence of structures representing the submucosal layer of the oesophageal wall. Results In total, 119 eligible patients underwent clinical response evaluations after nCRT followed by standard surgery. Residual tumour was present in endoscopic biopsies from 70 patients, confirmed on histological analysis of the resected organ. Residual tumour was present in the resection specimen from 27 of the other 49 patients, despite endoscopic biopsies being negative. Of these 27 patients, residual tumour was located in the mucosa in 18, and in the submucosa beneath tumour‐free mucosa in eight. One patient had tumour in muscle beneath tumour‐free mucosa and submucosa. Conclusion Most residual disease after nCRT missed by endoscopic biopsies was located in the mucosa. Active surveillance could be improved by more sampling and considering submucosal biopsies.Funding Information
- KWF Kankerbestrijding (EMCR 2014-7430)
This publication has 24 references indexed in Scilit:
- Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinomaBiochemical and Biophysical Research Communications, 2016
- Pathologists are able to differentiate reliably the lamina propria associated with Barrett's musculofibrous anomaly from submucosa in oesophageal endoscopic resectionsHistopathology, 2015
- Spatial-Temporal [18F]FDG-PET Features for Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiation TherapyInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerThe New England Journal of Medicine, 2012
- Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?Colorectal Disease, 2011
- Post-treatment Endoscopic Biopsy Is a Poor-Predictor of Pathologic Response in Patients Undergoing Chemoradiation Therapy for Esophageal CancerAnnals of Surgery, 2009
- Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The rotterdam experienceJournal of Surgical Oncology, 2009
- Diagnostic Yield of Tissue Sampling Using a Bite-On-Bite Technique for Incidental Subepithelial LesionsThe Korean Journal of Internal Medicine, 2009
- Yield of tissue sampling for subepithelial lesions evaluated by EUS: a comparison between forceps biopsies and endoscopic submucosal resectionGastrointestinal Endoscopy, 2006
- Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiationCancer, 2005